Latest Conference Articles

February 25th 2019, 2:12am

Transplantation and Cellular Therapy Meetings

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

February 25th 2019, 1:54am

Transplantation and Cellular Therapy Meetings

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

February 24th 2019, 1:18am

Transplantation and Cellular Therapy Meetings

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

February 23rd 2019, 10:27pm

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

February 23rd 2019, 10:25pm

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

February 23rd 2019, 9:49pm

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

February 23rd 2019, 2:33am

Transplantation and Cellular Therapy Meetings

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

February 23rd 2019, 12:46am

Transplantation and Cellular Therapy Meetings

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

February 22nd 2019, 11:31pm

Transplantation and Cellular Therapy Meetings

Shaji Kumar, MD, of Mayo Clinic, advises physicians on the use of autologous stem cell transplant in patients with newly diagnosed multiple myeloma.

February 22nd 2019, 11:14pm

Transplantation and Cellular Therapy Meetings

Frederick L. Locke, MD, discusses the optimal management of chimeric antigen receptor T-cell therapy-related adverse events.

February 22nd 2019, 8:44pm

Transplantation and Cellular Therapy Meetings

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

February 22nd 2019, 2:35am

Transplantation and Cellular Therapy Meetings

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

February 21st 2019, 7:26pm

Transplantation and Cellular Therapy Meetings

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

February 18th 2019, 10:25pm

Genitourinary Cancers Symposium (ASCO GU)

Arlene O. Siefker-Radtke, MD, discusses the promising preliminary data with bempegaldesleukin plus nivolumab in patients with metastatic urothelial carcinoma and the next steps for this combination.

February 18th 2019, 1:13am

Genitourinary Cancers Symposium (ASCO GU)

Single-agent pembrolizumab (Keytruda) showed encouraging antitumor activity as first-line treatment in patients with non-clear cell renal cell carcinoma, especially in those with papillary or unclassified histology.

February 18th 2019, 12:45am

Genitourinary Cancers Symposium (ASCO GU)

Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.

February 17th 2019, 9:23pm

Genitourinary Cancers Symposium (ASCO GU)

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of bempegaldesleukin plus nivolumab in the treatment of patients with metastatic urothelial carcinoma.

February 17th 2019, 9:20pm

Genitourinary Cancers Symposium (ASCO GU)

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

February 17th 2019, 7:53pm

Genitourinary Cancers Symposium (ASCO GU)

The overall response rate achieved with with the combination of savolitinib and durvalumabin in patients with metastatic papillary renal cell carcinoma in the phase II CALYPSO study did not meet the prespecified criterion for further investigation of the regimen.

February 17th 2019, 1:44am

Genitourinary Cancers Symposium (ASCO GU)

The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) has antitumor activity in patients with previously treated metastatic renal cell carcinoma and is tolerated at their separate approved doses for this indication.